News Sentiment

KMDA sentiment intelligence

Kamada news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 7.12 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

76/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend inactive

-5.1% over one week, -4.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Kamada highlights study results on CYTOGAM in transplants

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 76/100 classification
One-week reaction -5.1% Price reacting lower
Trend fit Trend inactive -4.3% over four weeks
Fair value 14.9% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 27
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 7
AD HOC NEWS 5
TradingKey 5
Investing.com 3
DonanımHaber 3
GuruFocus 2
GlobeNewswire 2
TradingView 2

Event Lens

What the news is about

Classified themes
Earnings 24
Market update 23
Regulatory and legal 6
Analyst action 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-56 of 56
Ad Hoc News Direct company coverage

Kamada Ltd stock (IL0010952647): shares stabilize after recent results as investors eye valuation me

Kamada Ltd (KMDA) shares are stabilizing on Nasdaq following its latest quarterly update, which provided fresh insight into its revenue and margin trends for 2025. Investors are now reassessing the Israeli biopharmaceutical group's earnings profile and valuation multiples, contri

Tone
Neutral 50/100
Event
Earnings
Published
29 May 2026 06:39
Source
Ad Hoc News
TradingView Direct company coverage

Kamada Q1 Earnings Call Highlights

Kamada reiterated its full-year 2026 outlook, with management stating that Q1 results were in line with expectations despite a temporary shipment delay. The company projects revenue of $200 million to $205 million and adjusted EBITDA of $50 million to $53 million for 2026, driven

Tone
Positive 67/100
Event
Earnings
Published
28 May 2026 00:40
Source
TradingView
Associated Press Direct company coverage

Kamada: Q1 Earnings Snapshot

Tone
Neutral 50/100
Event
Earnings
Published
13 May 2026 11:13
Source
Associated Press
Zacks Investment Research Direct company coverage

Should I buy Kamada (KMDA)

Tone
Positive 66/100
Event
Market update
Published
07 Jul 2016 23:49
Source
Zacks Investment Research